Skip to main content
OpenTrials
Completed

NCT Number: NCT04429334

Efficacy and Safety Study of Nangibotide in Patients With COVID-19 Receiving Ventilatory Support

This is a randomized, double-blind, placebo-controlled, in which one dose of nangibotide will be tested versus placebo.

All patients with a diagnosis of COVID-19, and a requirement for respiratory support will be considered for study participation. The applicable local requirements for informed consent will be followed. Where permissible, an emergency consent procedure will be followed for patients unable to provide consent by themselves. All potential study patients will receive standard of care treatment throughout the study. Patients will receive a continuous intravenous (i.v.) infusion of nangibotide at 1.0 mg/kg/h or a matching placebo. Treatment with study drug must be initiated as early as possible but no later than 48 hours after the initiation of ventilatory support (Patients will be treated for 5 days or until discharge from critical care, whichever is sooner). Follow-up visits will be performed on days 8 and 14. The end of study visit is at day 28. A further follow up visit will be undertaken on day 60.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Covid19 COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Clinique universitaire Saint-Luc, Brussels, Belgium

Loading trial locations.

About this study

ESSENTIAL was a randomized, double-blind, placebo-controlled trial, in which one dose of nangibotide was tested versus placebo. It took place in 14 sites in France and Belgium. The study was overseen by an independent Data Monitoring Committee (DMC).

The study was divided into two parts running sequentially without unblinding. Part 1 evaluated safety and tolerability study and included 60 patients, randomized in a 2:1 ratio of nangibotide to placebo. Part 2 included all recruited patients with an initially planned sample size of 370 patients, randomized in a 1:1 ratio of nangibotide to placebo.

All patients or their legally authorised representatives provided written informed consent or, in relevant countries, an independent physician, confirmed patient eligibility for enrolment in the trial.

Patients received a continuous intravenous infusion of nangibotide at 1.0 mg/kg/h or a matching placebo for 5 days (or until discharge from ICU, whichever was sooner). The treatment was in addition to standard of care.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Provided informed consent (emergency consent according to local regulations where approved)
  • Age 18 to 75 years (inclusive)
  • Admitted to an intensive care unit
  • Treatment with High Flow Nasal Oxygen, non-invasive ventilation or invasive mechanical ventilation for acute respiratory failure caused by COVID-19 for less than 48 hours
  • A PaO2:FiO2 ratio of <200mmHg (<26.7kPa) with a FiO2 ≥0.6
  • Confirmed laboratory diagnosis of COVID-19 within 7 days of meeting screening criteria

Exclusion criteria

  • Known pregnancy (positive urine or serum pregnancy test)
  • Ongoing treatment with an immunomodulatory agent not included in the standard of care for COVID-19 (including participation in clinical trials of such agents)".
  • Body mass index (BMI) ≥ 40 kg/m2or weight ≥ 130 kg
  • Anticipated transfer to another hospital, which is not a study site within 72 hours
  • Expected to die within 6 months of treatment due to underlying chronic disease
  • Limitations of care in place during current hospital admission

-

Treatment and study plan

nangibotide

Drug

nangibotide 1.0 mg/kg/h

Placebo

Drug

matching placebo

Primary outcomes

  1. Incidence of adverse events until day 28

    Time frame: 28 days

    Part 1

  2. Clinical Status (7-point Ordinal Scale) assessed at Day 28

    Time frame: 28 days

    Part 2

Sponsors and collaborators

Lead sponsor

Inotrem

Industry

Registry information

Official study title

Efficacy and Safety Study Exploring Nangibotide Treatment in COVID-19 pAtients With ventiLatory Support (ESSENTIAL) A Randomized, Double-blind, Placebo-controlled Study With Adaptive Features

Acronym: ESSENTIAL

Important dates

Study start
2020
Primary completion
2022
Study completion
2022
First posted
Jun 12, 2020
Registry last updated
May 3, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.